SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as investors react to the NOAA determination that the companys deep-seabed mining application is in full compliance, fueling community anticipation for accelerated permitting and long-term supply dominance. The broader conversation centers on the stock as a conviction-based play on the critical minerals supercycle, with community members actively discussing the strategic importance of domestic deep-sea mining to meet rising demand from AI and EV infrastructure.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is trending after reporting explosive earnings that significantly exceeded estimates, driven by a massive surge in AI-related data center demand. While some investors are engaging in profit-taking following the stock's parabolic climb, the community is actively debating whether the company's strong guidance, record margins, and new multibillion-dollar share buyback program signal a sustained supercycle or an unsustainable bubble.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is seeing massive volatility and high trading volume driven by a milestone payment from its Boehringer Ingelheim partnership, even as retail sentiment remains divided over the company's upcoming reverse stock split vote. Traders are actively debating whether the price action represents a legitimate fundamental catalyst or a speculative pump-and-dump setup, with many closely watching the stock for potential short-squeeze activity.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending after reporting record quarterly revenue and EPS, supported by robust iPhone demand and a massive new share buyback authorization. While investors are actively debating the impact of rising memory costs and the upcoming CEO transition to John Ternus, bullish sentiment remains focused on the company's strong services growth and potential long-term upside from AI integration.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit shares are surging after the company delivered a massive first-quarter beat, exceeding revenue and earnings estimates while providing strong guidance. The community remains highly focused on the stock's potential for a short squeeze and its long-term AI data licensing prospects, though some investors remain cautious about potential post-earnings volatility.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is facing significant downward pressure and intense community scrutiny following a major earnings miss, a downward revision of future bookings, and ongoing concerns regarding child safety and platform moderation. Investors are divided, with some viewing the sharp decline as a buying opportunity in a growth platform, while others are warning of continued volatility and fundamental risks.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian shares are surging following a robust quarterly performance that exceeded revenue and earnings expectations, bolstered by strong cloud growth and accelerated AI monetization. The community is actively debating whether this result signals a durable recovery for enterprise software or if the stock remains vulnerable to ongoing valuation and competition concerns.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global Holdings is trending following a strong first-quarter report where the company beat revenue estimates and raised its forward guidance, fueling community optimism around its accelerating AI-driven marketing growth. Investors are actively debating the sustainability of its 50% year-over-year revenue growth and debating the stock's potential for a short squeeze as they look for signs of a long-term re-rating phase.

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is experiencing extreme volatility and a massive short squeeze, driven by its ultra-low float and a borrow rate nearing 1,000%, which is forcing shorts to cover or face liquidation. Community sentiment is divided between retail bulls who are cheering the parabolic price action and skeptical traders warning of a potential rug-pull due to the company's history of reverse splits and weak fundamentals.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is currently trending as investors weigh a significant earnings beat against concerns over potential future dilution, highlighted by a freshly filed shelf offering and a restructured DOE loan. The community remains sharply divided, with bulls pointing to the long-term potential of the R2 production ramp and strategic partnerships, while bears emphasize ongoing cash burn, executive compensation, and the heavy reliance on Amazon for revenue.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Canaccord Genuity Group Lowers Compass Therapeutics (NASDAQ:CMPX) Price Target to $7.00

Canaccord Genuity Group dropped their price objective on shares of Compass Therapeutics from $13.00 to $7.00 and set a "buy" rating for the company in a report on Tuesday...

Citizens Jmp Reiterates Market Outperform Rating for Compass Therapeutics (NASDAQ:CMPX)

Citizens Jmp restated a "market outperform" rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Tuesday...

Compass Therapeutics (NASDAQ:CMPX) Hits New 12-Month Low  - What's Next?

Compass Therapeutics (NASDAQ:CMPX) Reaches New 52-Week Low - Here's Why...

Compass Therapeutics Touts Stunning PFS Win in COMPANION-002 as Crossover Muddy OS Data

Compass Therapeutics (NASDAQ:CMPX) executives highlighted what CEO and Vice Chair Dr. Thomas Schuetz called absolutely stunning progression-free survival results from the company's phase II/III...

Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients

Compass Therapeutics says tovecimig misses overall survival endpoint in biliary tract cancer study, but data shows progression-free survival and response rates.read more...

Compass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated a "buy" rating and issued a $30.00 price objective on shares of Compass Therapeutics in a report on Monday...

<ul class="summary-bullets"><li>The trial is testing Tovecimig in combination with Paclitaxel in patients with a rare disease affecting the bile ducts or gallbladder, often detected at an advanced stage.</li><li>The company expects to report progression-free survival and overall survival results.</li><li>Earlier data showed that the combination delivered an overall response rate of 17.1%, compared with 5.3% for Paclitaxel alone.</li></ul>Compass Therapeutics (CMPX), a biotech company focused on antibody-driven cancer treatments, drew strong retail interest on Monday as investors looked ahead to the upcoming topline data on secondary endpoints from its Phase 2/3 COMPANION-002 trial for advanced biliary tract cancerThe trial is testing Tovecimig in combination with Paclitaxel in patients with biliary tract cancer, a rare disease that affects the bile ducts or gallbladder, and is often detected at a late stage.At the time of writing, <a href="https://stocktwits.com/symbol/CMPX">CMPX shares</a> were down around 11% in pre-market trading. The stock has ended lower in five of the last six sessions.<h2 class="st-heading-2">Compass To Launch Separate Trial For Tovecimig</h2>The company expects to report progression-free survival (PFS) and overall survival (OS) results, marking a key milestone for the program. Tovecimig, a bispecific antibody, is being tested in combination with Paclitaxel in patients with advanced biliary tract cancer who have already received prior chemotherapy.Earlier data showed that the combination delivered an overall response rate of 17.1%, compared with 5.3% for Paclitaxel alone, a statistically significant improvement. The study also demonstrated lower disease progression rates in the combination arm.The randomized trial enrolled 168 patients, and safety findings to date are consistent with prior studies. Meanwhile, Compass also plans to launch a separate Phase 2 trial in mid-2026 to evaluate Tovecimig across a broader set of Delta-like ligand 4 (DLL4)-positive tumors. DLL4 is a protein that regulates blood vessel growth.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Despite the pre-market slide, retail sentiment on Stocktwits remained ‘extremely bullish’ over the past 24 hours, amid ‘extremely high’ message volumes.One user said that if the upcoming results beat existing standards, it could meaningfully improve treatment for advanced patients.<stembedurl>https://stocktwits.com/4Reel/message/651471837</stembedurl>The stock is down more than 1% so far in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

This Small-Cap Biotech Is Gearing Up For A Make-Or-Break Cancer Drug Data Drop

The biotech firm is set to report topline data on secondary endpoints from its Phase 2/3 trial for advanced biliary tract cancer on Monday.

CMPX Stock Has Retail Buzzing Ahead Of High-Stakes Cancer Drug Trial Update

Equity

M&T Bank Corp Makes New $4.10 Million Investment in Compass Therapeutics, Inc. $CMPX

M&T Bank Corp bought a new position in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 764,229 shares of the company's stoc...

Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen downgraded shares of Compass Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

CMPX
Compass Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CMPX News

CMPXCompass Therapeutics Inc